A new class of agents with powerful effects on cardiovascular outcomes has quickly amassed a compelling body of evidence for its use: sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Mayo Clinic mayocl.in/3tNMAdF
Follow Mayo Clinic on Instagram: / mayoclinic
Like Mayo Clinic on Facebook:
Follow Mayo Clinic on Twitter: / mayoclinic
28 сен 2024